Kornimate/medical-research-clean huggingface dataset:
quantitative evaluation of parafoveal microvasculature changes in eyes with exudative circumscribed choroidal haemangioma: an optical coherence tomography angiography study

Conditions: Circumscribed Choroidal Haemangioma; Optical Coherence Tomography Angiography; Macular

Summary: the study aims to quantitative evaluation of parafoveal microvasculature changes in eyes with exudative circumscribed choroidal haemangioma using optical coherence tomography angiography.

circumscribed choroidal haemangioma (cch) is an uncommon, potentially congenital benign vascular hamartomas which typically manifests as an elevated mass with reddish-orange pigmentation located posteriorly to the equator, mostly in the macular and peripapillary region. despite its benign nature, cystoid macular edema (cme) or srf due to the exudations from the exudative cch can cause visual impairment. diagnosis is often suspected clinically, and multimodal imaging is useful for the differential diagnosis of cch from other malignant tumors such as melanoma. optical coherence tomography angiography (octa) is a rapid, non-invasive, new imaging technology which could provide the capillary density (cd) of superficial and deep capillary plexus as well as the cd of choriocapillaris of the superficial, the latter two of which could not be seen on conventional fa or icga. however, little knowledge is known about the parafoveal microvasculature changes in eyes with exudative cch on octa. therefore, it is necessary to quantitative evaluation of parafoveal microvasculature changes in eyes with exudative cch compared with healthy eyes without any disease. to the best of our knowledge, this is the first cross-sectional, case-control study to use octa to quantitative evaluation of parafoveal microvasculature changes in eyes with exudative cch compared with age- and gender-controlled healthy eyes.

Eligibility criteria:
inclusion criteria: * for patients with exudative cch, the inclusion criteria were treatment naïve patients with exudative cch which caused subfoveal retinal detachment and/or intraretinal fluid. for the healthy eye control group, only one eye (randomized by computer) of a subject was included, and the included eyes should have no ocular diseases and the best-corrected visual acuity (bcva) should be 20/20 or better. exclusion criteria: * without any other ocular diseases or any severe uncontrolled systemic diseases, including uncontrolled hypertension, coronary heart disease, liver failure, and kidney failure. all the subjects with high diopter \> -6d, long eye axis \> 26.0 mm, or the quality of the acquired octa images below 7/10 should be excluded from this study.
shoe lifts for leg length inequality in adults with knee or hip symptoms

Conditions: Leg Length Inequality; Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: limb length inequality is when a person has one leg that is longer than the other. this research will look at correcting limb length inequality in adults with knee or hip symptoms. this study will examine whether ways of measuring leg length inequality in the clinic are valid and reliable, determine whether foot posture (flat foot, normal, and high arch) is related to leg length inequality, and determine whether shoe lifts are a helpful treatment for leg length inequality and knee/hip symptoms.

the purpose of this study is to examine the optimal clinical assessment method(s) for leg length inequality (lli), determine if there is an association between foot posture (flat foot, normal, and high arch) and lli, and gather preliminary data on lift therapy as a treatment for lli and knee/hip symptoms. the specific aims of the project are as follows: specific aim 1: determine the validity and reliability of 4 clinical methods for assessing lli. specific aim 2: determine differences in static and dynamic foot postures between longer and shorter limbs. specific aim 3: assess the feasibility of conducting a specific lift therapy intervention among individuals with a lli and knee or hip pain, refining procedures as needed. public health impact: results from the proposed research will be used to: 1) improve diagnosis of lli by providing evidence on the various assessment methods for the clinicians who most frequently use clinical methods (i.e., physical therapists, chiropractors, podiatrists, and primary care physicians), and 2) develop and test new non-pharmacologic/non-invasive intervention strategies aimed at reducing pain and improving function in individuals with osteoarthritis and lli.

Eligibility criteria:
inclusion criteria: * participants from the johnston county osteoarthritis project who have been previously identified to have a lli and knee or hip symptoms exclusion criteria: * hospitalized for stroke, myocardial infarction, coronary artery revascularization, or diagnosis of metastatic cancer in the past 3 months * terminal illness * rheumatoid arthritis, severe fibromyalgia, or other systemic rheumatic disease
effect of dry needling on gluteus medius contraction in greater trochanteric pain syndrome: a pilot rct protocol

Conditions: Greater Trocantheric Pain Syndrome

Summary: grater trochanteric pain syndrome is a hip related pathology that causes lateral hip pain and lack of strength in abductor muscles such as the gluteus medius, which hinders functional activities and daily life, such as standing, walking, sleeping on the affected side... lack of strength and eccentric control of the gluteus medius may be related to the apparition of myofascial trigger points that are susceptible to treatment with dry needling. in this study, two groups of patients with greater trochanteric pain syndrome will be treated with dry needling, some of them with real dry needling, and others with sham dry needling. ultrasound will be used to assess whether real dry needling in the pelvitrochanteric musculature improves the potential contraction of the gluteus medius, in relation to a baseline measurement and to sham dry needling. this study is a randomised clinical trial protocol, pilot study, so there will be no previous references for the sample of both study groups. 3 dry needling interventions will be performed in 3 consecutive weeks, leaving 1 week between each intervention. data will be collected for the variables to be investigated (potential contraction, pain, function, strength...) before the first intervention, after each intervention, 1 month after the last intervention and at 3 months.


Eligibility criteria:
inclusion criteria: * lateral hip pain lasting more than 3 months. * greater trochanteric pain syndrome compatible with changes on mri. * clinical examination correlation: one of the following tests must be positive: fader test, faber test, hip adduction (add) test in side-lying position (dl), isometric contraction test in the add position, or single-leg stance test for 30 seconds. * pain/sensitization upon palpation of the trochanter. exclusion criteria: * radicular pain due to lumbar pathology. * osteoarthritis. * pelvic pathology that could refer pain to the hip. * needle phobia. * hip injection performed less than 6 months ago. * dry needling performed less than 1 month ago. * surgery or pathology of the lower limb that prevents single-leg support. * systemic diseases that could interfere with the pathological process.

Keywords: greater trochanteric pain syndrome, potential contraction, dry needling, gluteus medius.
cervical neuromodulation and nociceptive processing

Conditions: Nociceptive Pain

Summary: several studies have demonstrated that direct currents delivered through the skin at the level of the lumbar spinal cord can influence spinal cord function. in human volunteers, anodal lumbar transcutaneous spinal direct current stimulation (tsdcs) alters spinal processing of nociceptive inputs. whether cervical tsdcs is able to do the same is less well known.

the investigators will compare the effects on the nociceptive processing of healthy volunteers of cervical and lumbar tsdcs. this study will be a double-blinded, sham-controlled, cross-over trial. each participant will undergo two experimental sessions (anodal cervical tsdcs and sham lumbar tsdcs vs. sham cervical tsdcs and anodal lumbar tsdcs), separated by at least one week.

Eligibility criteria:
inclusion criteria: - healthy young adults exclusion criteria: * known medical conditions (e.g., diabetes, neuropathy, psychiatric disorders, seizure, migraine, pacemaker or other implanted medical devices...) * use of any medication (except contraception)

Keywords: tsdcs non-invasive neuromodulation healthy volunteers
can waveform and flow traces from mechanical insuflattion:exsufflation (mi:e) be used to identify laryngeal responses to mi:e and thus optimise treatment algorithms?

Conditions: Neuromuscular Diseases

Summary: objectives: * to establish if physiotherapists can use the waveform traces from the cough assist machine to work out when patients are having an abnormal airway response to cough assist * to establish how cough assist device settings, particularly in breath and cough pressures affect a patient's response to using the cough assist device * to provide some clinical guidance to physiotherapists on methods for assessing and treating abnormal airway responses to cough assist devices methodology: subjects will complete breathing tests; spirometry, peak cough flow (pcf) and sniff nasal inspiratory pressure (snip) to establish baseline breathing function and rule out anyone with breathing conditions. a nasal camera will be used to look at the voice box at rest. cough assist will be delivered via a face mask which will allow for simultaneous use of the nasal camera and cough assist carried out in the same way as another research team have done previously. the nasal camera will be attached to a video camera to allow recording, analysis and documentation of the observations. the cough assist protocol will be delivered by a physiotherapist experienced in delivering cough assist. cough assist waveforms will be downloaded into care orchestrator software (philips respironics, murraysville, usa) and reviewed at the same time as the nose camera recordings to establish if voice box responses can be identified from the waveform patterns. for confirmation of care orchestrator software waveforms, a device that records airflow during breathing (spirometer) will be connected (alpha touch, vitalograph, ennis, ireland) into the cough assist circuit in the same way another research team has before.


Eligibility criteria:
inclusion criteria: * patients with neuromuscular disease(nmd) including but not limited to motor neurone disease (mnd), multiple sclerosis (ms) and muscular dystrophy * age ≥18 exclusion criteria: * unable to comply with protocol * unable to give informed consent * evidence of obstructive airways disease fev1:fvc \<0.7 * patients with a history of: * un-drained pneumothorax * severe bronchospasm * head injury with icp \> 25mmhg * severe arterial hypotension * trache-oesophageal fistula * significant haemoptysis * facial fractures * vomiting * flail segment * epistaxis within two weeks
using digitalized incentive spirometers to assist postoperative rehabilitation of abdominal surgery patients

Conditions: Bariatric Surgery Candidate; Sleep Apnea, Obstructive

Summary: the purpose of this clinical trial is to use a digital recording device integrated with an incentive spirometer to record a patient's deep breathing lung training following abdominal surgery. through this digital recording, it will be possible to effectively assess the daily frequency, duration, depth of deep breaths, and the volume of inhalation performed by the patient during their breathing exercises. this will transform the previously difficult-to-describe deep breathing training into a digital record, allowing healthcare professionals to quickly evaluate the patient's condition. patients can also monitor their own respiratory function changes, leading to positive health promotion benefits, accelerating their postoperative recovery, and simultaneously reducing healthcare costs and improving medical quality.

after thoracoabdominal and neurosurgery procedures, an incentive spirometer is commonly employed for deep breathing exercises to prevent or improve potential postoperative pulmonary atelectasis, increase lung capacity, promote the clearance of respiratory secretions, and maintain chest mobility to reduce postoperative complications related to lung collapse. this medical device and the respiratory training process are essential components of enhanced recovery after surgery (eras) protocols, which integrate postoperative care processes to enhance recovery, reduce hospitalization times, and minimize postoperative complications. currently, clinical guidelines typically recommend patients to perform 200-600 deep inhalations per day after surgery. despite the simplicity and effectiveness of using an incentive spirometer for deep breathing exercises, the observation of patients' usage, recording of the number and duration of exercises, and tracking of their deep inhalation volumes have become crucial tasks for respiratory therapists, nurses, and physicians in the postoperative setting, consuming significant time and resources. generally, using an incentive spirometer requires patients to perform 200-600 deep breaths a day. according to a 2018 medical literature estimate in the united states, approximately 9.7 million surgical procedures annually involve the use of incentive spirometers, with human resource costs for assisting patients in their use and assessing the effectiveness of their pulmonary rehabilitation reaching approximately one billion us dollars.

Eligibility criteria:
inclusion criteria: * 1. patients undergoing bariatric surgery * 2. patients could cooperate with conducting incentive spirometry before and after the operation. exclusion criteria: * 1. patients with contra-indication for incentive spirometry. * 2. patients could not deeply breathe with pulmonary vital capacity less than 10ml/kg. * 3. patients could not cooperate with conducting incentive spirometry before and after the operation. * 4. other causes judged by the principal investigator

Keywords: bariatric surgery incentive spirometry
a study of nasal glucagon in participants with a common cold

Conditions: Common Cold

Summary: the main purpose of this study is to evaluate the safety of nasal glucagon (ng) in participants with a common cold, some of whom will also take a nasal decongestant. the study will investigate how the body processes ng and the effect of ng on the body. the study will last up to 30 days for each participant.


Eligibility criteria:
inclusion criteria: * male or female participant presenting a score of 2 or 3 on nasal congestion and/or nasal discharge associated with at least one other symptom of common cold, as determined by the 8-item jackson cold scale at screening and prior to dosing of period 1. * participant with a body mass index (bmi) greater than or equal to 18.50 and below 30.00 kilogram per square meter (kg/m²). * light-, non- or ex-smokers. * have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, electrocardiogram \[ecg\] and urinalysis). exclusion criteria: * presence of any nose piercings. * history of significant hypersensitivity to glucagon, oxymetazoline or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs. * presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. * presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease. * presence of severe fever (more than 39.5 degrees celsius) at screening or prior to dosing of period 1. * presence of clinically significant findings on nasal examination or bilateral anterior rhinoscopy, such as structural abnormalities, nasal polyps, marked septal deviation, nasal tumors. * presence or history of type 1 or type 2 diabetes. * presence or history of significant hypoglycemia or hyperglycemia. * use of beta-blockers, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before day 1 of the study. * fasting blood glucose above 6.1 mmol/l at screening, following a 12-hour fasting period. * fasting blood glucose assessed with a glucose meter above 6.1 mmol/l approximately 0.5 hour before each dosing.
changes of pressure on soft tissue before and after total hip replacement to prevent bedsores

Conditions: Transient Arthropathy of Hip

Summary: patients candidates for total hip replacement are, generally elderlies and have hip pain, we will check if the pressure to the soft tissue changes before and after operation using a tapet with pressure sensors sending the information to specific software.

one hundred patients 60 years old and more will be considered for this study, both sexs, that have schedule for elective unilateral total hip replacement and have not bedsores previously. all the data will be collected by fsa software, classified in an excel table. a crossover study will be performed and analyzed by a paired test.

Eligibility criteria:
inclusion criteria: 60 y/o/ and more * both sexes * schedule for total hip replacement exclusion criteria: * patient with previous bedsore * patients under 60 y.0. * previous cva

Keywords: bedsores pressure hip
milk-only lactation study for patients on eltrombopag

Conditions: Thrombocytopaenia

Summary: this is a phase iv study to evaluate eltrombopag concentrations in breast milk of nursing mothers taking marketed eltrombopag (promacta®). up to 10 subjects (mother-infant pairs) at as many as 10 study centers in the us will be enrolled. nursing mothers who are registered with the promacta pregnancy registry will be offered the option to participate in this trial if they continue to take commercial eltrombopag post-delivery and decide to breastfeed their infant. information will be collected in a diary. breast milk samples will be collected before and after infant feedings for a 24 hour period after eltrombopag dosing to evaluate the eltrombopag concentrations in the breast milk. mothers will also be given the option to have a pharmacokinetic (pk) blood sample collected from the infant.


Eligibility criteria:
inclusion criteria: * mother is registered with the promacta pregnancy registry and meets all the enrollment criteria defined in the promacta pregnancy registry study (113327). * mother is continuing to take eltrombopag. * mother has received 7 consecutive eltrombopag doses prior to the milk sample collection. * infant is 4 weeks to 26 weeks of age at the time of milk sampling. * exclusively breastfeeding mother-infant pair; either via breast or with expressed milk from the mother. * mother is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. exclusion criteria: * infant was born with complications that could impact ability to participate in this study. * breastfeeding is not well established in the mother-infant pair (e.g., poor latching of the infant or low milk supply). * infants who are supplemented with formula or are consuming solid foods. * unwillingness or inability of mother to follow the procedures outlined in the protocol. * mother is mentally or legally incapacitated

Keywords: eltrombopag pharmacokinetics promacta lactation milk-only study
rhythmical massage compared with heart rate variability biofeedback in women with menstrual pain (dysmenorrhea)

Conditions: Primary Dysmenorrhea

Summary: a study to explore whether rhythmical massage and heart rate variability biofeedback can help to reduce pain in women suffering from menstrual pain (dysmenorrhea).

this is a three-arm randomized controlled trial to evaluate the efficacy of rhythmical massage and hrv biofeedback in women with primary dysmenorrhea compared to a control group. the main focus is on pain intensity during menstruation. moreover, analgesics intake, sf-12 mental and physical scores and parameters of a 24h-hrv measurement are assessed before and after the three-month intervention.

Eligibility criteria:
inclusion criteria: * at least one year of primary dysmenorrhea (physician-confirmed). * written informed consent (also from parents/legal guardians of underage girls). * menarche at least one year ago. exclusion criteria: * secondary dysmenorrhea. * participation in another study. * mental retardation. * addiction.

Keywords: dysmenorrhea women health rhythmical massage anthroposophic medicine hrv biofeedback
pharmacovigilance study of keppra. spain - skate : safety of keppra as adjunctive therapy in epilepsy

Conditions: Epilepsy, Partial

Summary: patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study * to assess the safety and tolerability of keppra (levetiracetam) and to confirm the favorable safety of the drug found during clinical development * to obtain further information about optimal dosing in daily clinical practice. compared to previous registration trials, the study population corresponded more closely to that seen in daily clinical practice.


Eligibility criteria:
inclusion criteria: * male and female older than 16 years; * epilepsy with partial onset seizures, with or without secondary generalization; * at least one concomitant marketed anti-epileptic drug exclusion criteria: * safety reasons

Keywords: levetiracetam keppra
n-acetylcysteine to reduce infection and mortality for alcoholic hepatitis

Conditions: Alcoholic Hepatitis; Infection

Summary: recent data have suggested that monocyte oxidative burst defect is associated with the development of infection in patients with severe alcoholic hepatitis. one report found reduced 28 day mortality in patients treated with n-acetylcysteine combined with prednisolone when compared to prednisolone alone. the current study seeks to reveal whether the mechanism by which nac reduces susceptibility to infection is through improvement of phagocyte oxidative burst.

randomised controlled trial, open label.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * clinical alcoholic hepatitis: * serum bilirubin \>80umol/l * history of alcohol excess (\>80g/day male, \>60g/day female) * less than 4 weeks since admission to hospital * maddrey's discriminant function (df) \>32 * informed consent exclusion criteria: * alcohol abstinence of \>6 weeks prior to randomisation * duration of jaundice \>3 months * other causes of liver disease including: * evidence of viral hepatitis (hepatitis b or c) * biliary obstruction * hepatocellular carcinoma * evidence of current malignancy (except non-melanotic skin cancer) * previous entry into the study * patients with known hypersensitivity or previous reactions to nac * pregnant or lactating women